Sami Labs Limited

Other

Sami-sabinsa Group Limited

Semi Labs Limited

Majeed, Muhammed

Nagabhushanam, Kalyanam

Pandey, Anjali

Majeed, Anju

Thomas, Samuel Manoharan

Bani, Sarang

Anju Majeed

Muhammed Majeed

Kalyanam Nagabhushanam

Anjali Pandey

Sarang Bani

Sivakumar Arumugam

Furqan Ali

Samuel Manoharan Thomas

Kirankumar Beede

Muthuraman Gnanamani

Krishnamurthy Kulithalai Viswanathan

Bani Sarang

Jamsheeda Moothedath

John Adams Sebastian

Samuel Thomas Manoharan

Nooruddin Thajuddin

The present invention discloses a novel endophytic fungi,MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes ofsp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungiMTCC 25236 and bacterial species,and

Microbial bioconversion of curcuminoids to calebin-A

The present invention discloses the potential of Calebin A in attenuating high fat diet (HFD) induced hepatic steatosis in mammals.

Calebin A for hepatic steatosis

Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.

Method for the treatment of hypercholesterolemia

Disclosed is a simple, economical, industrially scalable green synthetic process for Calebin-A and its biologically active analogs.

Synthesis of calebin-A and its biologically active analogs

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-&#x3b1;), Interleukin-6 (IL-6) and Interleukin-1 (IL-1&#x3b2;).

Anti-obesity potential of Calebin A

Growing community of inventors

Piscataway, NJ, United States of America

Anju Majeed